Novo Nordisk has officially launched Wegovy, the first and only oral GLP-1 medication for obesity, now available in pharmacies throughout the United States. This daily pill provides an alternative to the previously required weekly injections. The starter dose is priced at $149 per month for cash-paying patients. The introduction of Wegovy has triggered a price war among weight-loss drugs, with promises of an abundant supply to meet demand. This launch marks a significant milestone in the availability of weight-loss options, as consumers can now acquire this medication more easily and affordably. GoodRx has also partnered to offer competitive pricing for the Wegovy pill, expanding access to this new treatment in the weight-loss market.